InDex Pharmaceuticals originated from research at the Karolinska Institutet in Stockholm, Sweden and was incorporated in 2001. The Company is targeting inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) for which current therapeutic approaches are ineffective or non-existent. 

The need for better treatment of patients suffering from UC is substantial. InDex has significant clinical evidence from compassionate use of Cobitolimod, its lead drug candidate, that it is possible to achieve immunological response to the therapy and achieve disease remission over lengthy periods of time and thus prevent or postpone colectomy.